Rankings
▼
Calendar
▼
EPRX Q3 2019 Earnings Report — Eupraxia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
Eupraxia Pharmaceuticals Inc.
EPRX
Q3 2019 Earnings
Reported September 29, 2019
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q3 2019
Q2 2019
Q3 2018
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$871.3K
—
—
—
—
EPS (Diluted)
$-0.10
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$392.9K
Selling & Marketing
$0
General & Administrative
$451.1K
SG&A Expenses
$451.1K
Other Expenses
$27.3K
Operating Expenses
$871.3K
Cost & Expenses
$871.3K
OPERATING INCOME
-$871.3K
Interest Income
$6.3K
Interest Expense
$202.6K
Other Income/Expenses
-$99.8K
INCOME BEFORE TAX
-$971.1K
Income Tax Expense
$0
Net Income from Continuing Ops
-$971.1K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$963.3K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$963.3K
D&A
$27.3K
EBIT
-$768.5K
EBITDA
-$741.2K
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
← Q3 2020
EPRX Overview